NeoGenomics, Inc. (NEO)
USD 8.28
(-5.75%)
USD 8.28
(-5.75%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.68 Billion USD | -3.38% |
| 2022 | 1.74 Billion USD | -6.94% |
| 2021 | 1.86 Billion USD | 89.19% |
| 2020 | 988.33 Million USD | 39.3% |
| 2019 | 709.5 Million USD | 40.49% |
| 2018 | 505.01 Million USD | 47.09% |
| 2017 | 343.34 Million USD | 1.85% |
| 2016 | 337.11 Million USD | -8.38% |
| 2015 | 367.95 Million USD | 353.67% |
| 2014 | 81.1 Million USD | 103.19% |
| 2013 | 39.91 Million USD | 32.74% |
| 2012 | 30.07 Million USD | 50.74% |
| 2011 | 19.94 Million USD | 46.14% |
| 2010 | 13.65 Million USD | 5.45% |
| 2009 | 12.94 Million USD | 77.45% |
| 2008 | 7.29 Million USD | 11.88% |
| 2007 | 6.52 Million USD | 108.21% |
| 2006 | 3.13 Million USD | 189.97% |
| 2005 | 1.08 Million USD | 82.45% |
| 2004 | 591.99 Thousand USD | 16.76% |
| 2003 | 507.03 Thousand USD | 13.22% |
| 2002 | 447.83 Thousand USD | 450.56% |
| 2001 | 81.34 Thousand USD | 43632.8% |
| 2000 | 186.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.64 Billion USD | -2.43% |
| 2024 Q3 | 1.64 Billion USD | -0.13% |
| 2024 Q2 | 1.64 Billion USD | 0.18% |
| 2023 FY | 1.68 Billion USD | -3.38% |
| 2023 Q2 | 1.69 Billion USD | -0.82% |
| 2023 Q3 | 1.67 Billion USD | -1.0% |
| 2023 Q1 | 1.7 Billion USD | -1.77% |
| 2023 Q4 | 1.68 Billion USD | 0.18% |
| 2022 Q1 | 1.82 Billion USD | -2.15% |
| 2022 Q2 | 1.79 Billion USD | -2.05% |
| 2022 Q3 | 1.75 Billion USD | -2.04% |
| 2022 Q4 | 1.74 Billion USD | -0.89% |
| 2022 FY | 1.74 Billion USD | -6.94% |
| 2021 Q1 | 1.49 Billion USD | 51.21% |
| 2021 Q2 | 1.89 Billion USD | 26.89% |
| 2021 Q3 | 1.9 Billion USD | 0.53% |
| 2021 Q4 | 1.86 Billion USD | -1.92% |
| 2021 FY | 1.86 Billion USD | 89.19% |
| 2020 Q4 | 988.33 Million USD | 3.01% |
| 2020 Q3 | 959.42 Million USD | 1.47% |
| 2020 Q1 | 732.24 Million USD | 3.21% |
| 2020 FY | 988.33 Million USD | 39.3% |
| 2020 Q2 | 945.48 Million USD | 29.12% |
| 2019 Q2 | 696.66 Million USD | 30.62% |
| 2019 Q1 | 533.34 Million USD | 5.61% |
| 2019 Q3 | 711.15 Million USD | 2.08% |
| 2019 Q4 | 709.5 Million USD | -0.23% |
| 2019 FY | 709.5 Million USD | 40.49% |
| 2018 Q3 | 455.13 Million USD | 31.63% |
| 2018 FY | 505.01 Million USD | 47.09% |
| 2018 Q2 | 345.78 Million USD | -1.0% |
| 2018 Q1 | 349.27 Million USD | 1.73% |
| 2018 Q4 | 505.01 Million USD | 10.96% |
| 2017 Q3 | 343.89 Million USD | 1.18% |
| 2017 Q4 | 343.34 Million USD | -0.16% |
| 2017 FY | 343.34 Million USD | 1.85% |
| 2017 Q1 | 343.63 Million USD | 1.93% |
| 2017 Q2 | 339.88 Million USD | -1.09% |
| 2016 Q1 | 346.84 Million USD | -5.74% |
| 2016 FY | 337.11 Million USD | -8.38% |
| 2016 Q4 | 337.11 Million USD | -5.15% |
| 2016 Q3 | 355.42 Million USD | 1.1% |
| 2016 Q2 | 351.55 Million USD | 1.36% |
| 2015 Q3 | 83.74 Million USD | 0.93% |
| 2015 Q4 | 367.95 Million USD | 339.4% |
| 2015 Q2 | 82.96 Million USD | 2.23% |
| 2015 Q1 | 81.15 Million USD | 0.06% |
| 2015 FY | 367.95 Million USD | 353.67% |
| 2014 Q3 | 78.82 Million USD | 80.62% |
| 2014 Q2 | 43.63 Million USD | 3.12% |
| 2014 Q4 | 81.1 Million USD | 2.9% |
| 2014 FY | 81.1 Million USD | 103.19% |
| 2014 Q1 | 42.31 Million USD | 6.02% |
| 2013 FY | 39.91 Million USD | 32.74% |
| 2013 Q4 | 39.91 Million USD | 13.3% |
| 2013 Q3 | 35.23 Million USD | 2.24% |
| 2013 Q2 | 34.45 Million USD | 2.51% |
| 2013 Q1 | 33.61 Million USD | 11.79% |
| 2012 FY | 30.07 Million USD | 50.74% |
| 2012 Q1 | 26.44 Million USD | 32.54% |
| 2012 Q4 | 30.07 Million USD | 2.62% |
| 2012 Q2 | 28 Million USD | 5.9% |
| 2012 Q3 | 29.3 Million USD | 4.65% |
| 2011 FY | 19.94 Million USD | 46.14% |
| 2011 Q4 | 19.94 Million USD | 14.09% |
| 2011 Q3 | 17.48 Million USD | 4.96% |
| 2011 Q2 | 16.65 Million USD | 8.17% |
| 2011 Q1 | 15.4 Million USD | 12.81% |
| 2010 Q3 | 14.28 Million USD | -2.53% |
| 2010 FY | 13.65 Million USD | 5.45% |
| 2010 Q1 | 14.21 Million USD | 9.83% |
| 2010 Q4 | 13.65 Million USD | -4.41% |
| 2010 Q2 | 14.65 Million USD | 3.05% |
| 2009 Q1 | 8.81 Million USD | 20.86% |
| 2009 FY | 12.94 Million USD | 77.45% |
| 2009 Q2 | 9.38 Million USD | 6.4% |
| 2009 Q3 | 12.91 Million USD | 37.69% |
| 2009 Q4 | 12.94 Million USD | 0.22% |
| 2008 Q4 | 7.29 Million USD | -9.12% |
| 2008 Q2 | 7.66 Million USD | 23.2% |
| 2008 Q1 | 6.22 Million USD | -4.59% |
| 2008 FY | 7.29 Million USD | 11.88% |
| 2008 Q3 | 8.02 Million USD | 4.72% |
| 2007 Q2 | 6.51 Million USD | 52.46% |
| 2007 Q1 | 4.27 Million USD | 36.4% |
| 2007 Q4 | 6.52 Million USD | 3.13% |
| 2007 FY | 6.52 Million USD | 108.21% |
| 2007 Q3 | 6.32 Million USD | -2.92% |
| 2006 Q1 | 2.03 Million USD | 88.14% |
| 2006 Q3 | 2.97 Million USD | 27.89% |
| 2006 Q2 | 2.32 Million USD | 14.34% |
| 2006 Q4 | 3.13 Million USD | 5.4% |
| 2006 FY | 3.13 Million USD | 189.97% |
| 2005 Q3 | 998.65 Thousand USD | 25.86% |
| 2005 FY | 1.08 Million USD | 82.45% |
| 2005 Q1 | 727.18 Thousand USD | 22.84% |
| 2005 Q2 | 793.44 Thousand USD | 9.11% |
| 2005 Q4 | 1.08 Million USD | 8.16% |
| 2004 Q3 | 756.98 Thousand USD | 20.71% |
| 2004 FY | 591.99 Thousand USD | 16.76% |
| 2004 Q2 | 627.13 Thousand USD | 18.13% |
| 2004 Q4 | 591.99 Thousand USD | -21.8% |
| 2004 Q1 | 530.87 Thousand USD | 4.7% |
| 2003 Q4 | 507.03 Thousand USD | 4.73% |
| 2003 Q1 | 479.72 Thousand USD | 7.12% |
| 2003 FY | 507.03 Thousand USD | 13.22% |
| 2003 Q2 | 488.91 Thousand USD | 1.91% |
| 2003 Q3 | 484.12 Thousand USD | -0.98% |
| 2002 Q3 | 468.44 Thousand USD | 48.02% |
| 2002 Q2 | 316.47 Thousand USD | 55.26% |
| 2002 FY | 447.83 Thousand USD | 450.56% |
| 2002 Q1 | 203.84 Thousand USD | 150.6% |
| 2002 Q4 | 447.83 Thousand USD | -4.4% |
| 2001 FY | 81.34 Thousand USD | 43632.8% |
| 2001 Q4 | 81.34 Thousand USD | 26139.68% |
| 2001 Q3 | 310.00 USD | 287.5% |
| 2001 Q1 | 500.00 USD | 168.82% |
| 2001 Q2 | 80.00 USD | -84.0% |
| 2000 Q3 | 3808.00 USD | -98.22% |
| 2000 Q1 | 267.49 Thousand USD | 0.0% |
| 2000 FY | 186.00 USD | 0.0% |
| 2000 Q4 | 186.00 USD | -95.12% |
| 2000 Q2 | 213.75 Thousand USD | -20.09% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -751.665% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -12215.273% |
| Aspira Women's Health Inc. | 6.26 Million USD | -26748.116% |
| Biodesix, Inc. | 99.09 Million USD | -1596.566% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -14647.891% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -20349.047% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -20349.047% |
| Bionano Genomics, Inc. | 214.4 Million USD | -684.141% |
| CareDx, Inc | 484.61 Million USD | -246.921% |
| Check-Cap Ltd. | 25.01 Million USD | -6620.346% |
| Castle Biosciences, Inc. | 477.81 Million USD | -251.861% |
| DarioHealth Corp. | 96.38 Million USD | -1644.213% |
| Exact Sciences Corporation | 6.47 Billion USD | 74.02% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | -32.057% |
| Guardant Health, Inc. | 1.78 Billion USD | 5.888% |
| ICON Public Limited Company | 16.98 Billion USD | 90.105% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 48.427% |
| Illumina, Inc. | 10.11 Billion USD | 83.372% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -12101.507% |
| iSpecimen Inc. | 15.81 Million USD | -10527.817% |
| Standard BioTools Inc. | 323.06 Million USD | -420.396% |
| MDxHealth SA | 129.13 Million USD | -1201.946% |
| 23andMe Holding Co. | 395.16 Million USD | -325.448% |
| Medpace Holdings, Inc. | 1.65 Billion USD | -1.473% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -40.254% |
| Mainz Biomed B.V. | 15.4 Million USD | -10810.675% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -24791.807% |
| Neogen Corporation | 4.58 Billion USD | 63.325% |
| Inotiv, Inc. | 856.53 Million USD | -96.284% |
| Natera, Inc. | 1.45 Billion USD | -15.38% |
| OpGen, Inc. | 1.88 Million USD | -89219.036% |
| OPKO Health, Inc. | 2.01 Billion USD | 16.427% |
| Psychemedics Corporation | 13.27 Million USD | -12569.397% |
| Prenetics Global Limited | 254.17 Million USD | -561.457% |
| Prenetics Global Limited | 254.17 Million USD | -561.457% |
| Precipio, Inc. | 18.1 Million USD | -9188.045% |
| Personalis, Inc. | 225.09 Million USD | -646.884% |
| RadNet, Inc. | 2.88 Billion USD | 41.759% |
| Sera Prognostics, Inc. | 95.44 Million USD | -1661.537% |
| Sotera Health Company | 3.13 Billion USD | 46.294% |
| Neuronetics, Inc. | 115.83 Million USD | -1351.45% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -1833.025% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -1833.025% |
| Trinity Biotech plc | 59.43 Million USD | -2728.685% |
| T2 Biosystems, Inc. | 34.79 Million USD | -4731.534% |
| Twist Bioscience Corporation | 776.4 Million USD | -116.541% |
| Exagen Inc. | 56.94 Million USD | -2852.425% |